Skip to main content

PAINWeek 2023 Main banner

Icon Legend

This session is not in your agenda.

This session is in your agenda. Click to remove it

Back

Michelle Finnegan, MS

Executive Director, Neuroscience Development
AbbVie
Madison, New Jersey

Disclosure information not submitted.

Presentation(s):

Efficacy of Ubrogepant for the Treatment of Migraine Symptoms During the Prodrome (Premonitory Phase): Results From the PRODROME Trial
POSTER ABSTRACT
Ubrogepant for the Acute Treatment of Migraine When Administered During the Prodrome (Premonitory Phase): Results From a Phase 3, Randomized, Double-blind, Placebo-Controlled, Crossover Study
POSTER ABSTRACT